Maze Therapeutics (Ticker: MAZE) is a clinical-stage biopharmaceutical company. The company develops small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic diseases, including obesity. Their Compass platform allows them to identify and characterize genetic variants in disease and link those variants to the biological pathways that drive disease in specific patient groups. Maze Therapeutics is advancing two wholly-owned lead programs, MZE829 and MZE782, for chronic kidney disease (CKD).

Maze Therapeutics will list on January 31, 2025, on NASDAQ. The firm is selling 7.8 million shares at the price range of $15.00-$17.00. The expected Market Capitalization at offer is $685.23 million. The total offer size is $124.8 million. The offering is managed by J.P. Morgan/TD Cowen/Leerink/Guggenheim Securities.